Earnings guidance is conservative according to them. However, 2nd half will be hurt by more than .04 eps because Glaxo is not going to produce as much seasonal flu vaccine, and at this point, they are not forecasting increased revenues from swine flu. It is even possible, government will offer swine flu vaccine for nothing.